Insights to Optimizing Therapeutic Approaches for T-cell lymphomas
T-cell lymphomas are a heterogeneous group of lymphoproliferative disorders that account for 15% of all non-Hodgkin lymphomas (NHLs). The majority of these are peripheral T-cell lymphomas (PTCL). T-cell lymphomas are highly variable in their clinical presentation and prognosis. Research over the past few decades has revealed that these malignancies are biologically distinct with unique molecular, pathologic, and clinical features. This understanding has led to greater classification of T-cell lymphomas into separate subtypes. The identification of these malignancies as distinct entities is improving outcomes for patients with PTCL by enabling greater individualization of therapy and identifying new therapeutic targets.
The challenges faced by clinicians and patients in trying to optimize treatment strategies for peripheral and cutaneous T-cell lymphoma are continually evolving. As advances are made in the understanding of disease subtypes, mechanisms of disease, diagnostic indicators, new drug development and the rationale for new combinations of therapies, decision making about treatment options will become more complex as these considerations are applied to practice. Clearly, the heterogeneity of T-cell lymphomas presents an increasingly complex framework within which clinicians must be comfortable in order to accurately diagnose and stage the disease, and to make the best treatment decisions based on the most recent clinical evidence.
With recent advances in the management of T-cell lymphoma physicians need to understand the evolving data so that they can begin to apply them in the clinical setting. They are also encouraged to enroll patients in clinical trials as this is the only way researchers can improve the therapy for these patients.
This one-hour educational activity will address key issues related to accurate diagnosis and will feature faculty analysis of recent clinical data and evidence-based practice guidelines, along with interactive discussions on emerging therapeutic strategies for T-cell lymphomas. In addition, the curriculum will address current challenges faced by clinicians, and will provide expert opinion on how to deal with common issues encountered in identifying appropriate therapies and clinical trials for PTCL and CTCL patients.
This educational program is directed toward medical oncologists, hematologists, pathologists and hematopathologists interested in the diagnosis and treatment of patients with peripheral and cutaneous T-cell lymphoma. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the diagnosis and treatment of PTCL and CTCL are also invited to attend.
After completing this program, participants should be able to:
1. Distinguish between the various T-cell lymphoma subtypes and recognize histopathologic, clinical and the molecular, features that aid in accurate diagnosis and guide treatment decisions.
2. Describe current treatment options for peripheral (PTCL) and cutaneous (CTCL) T-cell lymphoma subtypes and how recent clinical trials data with existing and emerging agents can be integrated into evidence-based clinical management strategies.
3. Evaluate the efficacy and safety data from studies of current and emerging treatment options to improve outcomes in patients with PTCL and CTCL.
4. Summarize new data and possible treatment algorithms that can be used in community practice to achieve the best outcomes for patients PTCL and CTCL.
5. Understand current evidence regarding the role of bone marrow transplantation in PTCL and CTCL
Physician Accreditation Statement:
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship of Medical Education Resources (MER) and PleXus Communications. MER is accredited by the ACCME to provide continuing medical education for physicians.
Medical Education Resources designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.
Medical Education Resources is an approved provider of continuing education by the Colorado Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.
This CE activity provides 1.0 contact hours of continuing nursing education.
Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 1.0 contact hour.
Disclosures of Conflicts of Interest:
It is the policy of Medical Education Resources (MER) to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to contrl the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported or used in CME activity conforms to the generally accepted standards of experimental design, data collection, and analysis.
There is no fee for this educational activity.
Andrei R. Shustov, MD (Chair)
Assistant Professor, Hematology Division, University of Washington School of Medicine
Assistant Member, Fred Hutchinson Cancer Research Center
Seattle Cancer Care Alliance
James O. Armitage, MD
Professor, Department of Internal Medicine
Joe Shapiro Distinguished Chair of Oncology
University of Nebraska Medical Center
Michelle Fanale, MD
Assistant Professor in the Department of Lymphoma/Myeloma, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Steven M. Horwitz, MD
Memorial Sloan Kettering Cancer Center
New York, NY
John Pagel, MD, PhD
Swedish Cancer Institute
Barbara Pro, MD
Director, Cutaneous Lymphoma Center
Lauren Pinter-Brown MD
Ronald Reagan UCLA Medical Center
Los Angeles, CA